Homology Medicines, Inc. appointed Albert Seymour, Ph.D., to serve as its President and Chief Executive Officer (CEO). Dr. Seymour previously drove the translation of the company's proprietary in vivo gene therapy and nuclease-free gene editing platforms from early discovery into clinical development stages. He has extensive executive and research leadership background in the life sciences sector, including senior roles at Pfizer and Shire.